Lifecore Biomedical (LFCR) Aperçu de l'action
Lifecore Biomedical, Inc. et ses filiales opèrent en tant qu'organisation intégrée de développement et de fabrication sous contrat qui sert des clients aux États-Unis, en Belgique, aux Pays-Bas et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
LFCR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lifecore Biomedical, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$4.75 |
| Plus haut sur 52 semaines | US$8.98 |
| Plus bas sur 52 semaines | US$3.63 |
| Bêta | 1.06 |
| Variation sur 1 mois | -16.52% |
| Variation sur 3 mois | 0% |
| Variation sur 1 an | -42.77% |
| Variation sur 3 ans | -51.83% |
| Variation sur 5 ans | -59.02% |
| Évolution depuis l'introduction en bourse | -62.75% |
Nouvelles et mises à jour récentes
Article d’analyse • Jun 30
Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?
Lifecore Biomedical, Inc. ( NASDAQ:LFCR ), is not the largest company out there, but it received a lot of attention...
Mise à jour du récit • Jun 26
LFCR: New Pharma Agreements Will Shape A Measured Outlook Ahead
Lifecore Biomedical’s analyst price target has moved to $6.50, a $0.50 increase that analysts link to recent agreements with global pharmaceutical partners, as well as greater confidence in the company’s ability to expand its clinical reach and execute on its plans. Analyst Commentary Recent Street research on Lifecore Biomedical centers on the updated US$6.50 price target, which is tied to new agreements with global pharmaceutical partners and increased confidence in the company’s ability to carry out its plans.
Mise à jour du récit • Jun 11
LFCR: CDMO Site Transfers And 2028 Ramps Will Drive Long Term Upside
Narrative Update on Lifecore Biomedical The analyst price target for Lifecore Biomedical has been reset to $5, reflecting a balance between a $5.50 target tied to expectations for a later breakout year and a $5 target that factors in softer FY26 guidance and delayed commercial ramps, which analysts generally view as timing related rather than a shift in the long term opportunity. Analyst Commentary Recent Street research on Lifecore Biomedical reflects a mix of optimism about the long term setup and caution around the near term execution and guidance.Mise à jour du récit • May 28
LFCR: CDMO Site Transfers And 2028 Ramps Will Support Future Upside
Narrative Update: Lifecore Biomedical Analysts have adjusted their average price target for Lifecore Biomedical toward $5 to $5.50, reflecting mixed recent research in which one firm lifted its target by $0.50 while another reduced its target by $3.50. The firms cited the timing of commercial ramps and a slightly later potential breakout year as key drivers.Recent updates
Article d’analyse • Jun 30
Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?
Lifecore Biomedical, Inc. ( NASDAQ:LFCR ), is not the largest company out there, but it received a lot of attention...Mise à jour du récit • Jun 26
LFCR: New Pharma Agreements Will Shape A Measured Outlook Ahead
Lifecore Biomedical’s analyst price target has moved to $6.50, a $0.50 increase that analysts link to recent agreements with global pharmaceutical partners, as well as greater confidence in the company’s ability to expand its clinical reach and execute on its plans. Analyst Commentary Recent Street research on Lifecore Biomedical centers on the updated US$6.50 price target, which is tied to new agreements with global pharmaceutical partners and increased confidence in the company’s ability to carry out its plans.Mise à jour du récit • Jun 11
LFCR: CDMO Site Transfers And 2028 Ramps Will Drive Long Term Upside
Narrative Update on Lifecore Biomedical The analyst price target for Lifecore Biomedical has been reset to $5, reflecting a balance between a $5.50 target tied to expectations for a later breakout year and a $5 target that factors in softer FY26 guidance and delayed commercial ramps, which analysts generally view as timing related rather than a shift in the long term opportunity. Analyst Commentary Recent Street research on Lifecore Biomedical reflects a mix of optimism about the long term setup and caution around the near term execution and guidance.Mise à jour du récit • May 28
LFCR: CDMO Site Transfers And 2028 Ramps Will Support Future Upside
Narrative Update: Lifecore Biomedical Analysts have adjusted their average price target for Lifecore Biomedical toward $5 to $5.50, reflecting mixed recent research in which one firm lifted its target by $0.50 while another reduced its target by $3.50. The firms cited the timing of commercial ramps and a slightly later potential breakout year as key drivers.Mise à jour du récit • May 01
LFCR: CDMO Site Transfers And 2028 Commercial Ramps Will Drive Upside
Narrative update on Lifecore Biomedical The updated analyst price target for Lifecore Biomedical moves to $6.67 from $6.50. Analysts point to slightly higher modeled fair value, a modestly adjusted discount rate, incremental changes to revenue growth and margin assumptions, and a higher future P/E multiple following recent target revisions and rating changes.Mise à jour du récit • Apr 16
LFCR: CDMO Site Transfers And 2028 Pipeline Ramps Will Drive Upside
Narrative Update: Lifecore Biomedical The analyst price target on Lifecore Biomedical has shifted to a range centered around $5 to $5.50, reflecting reactions to softer FY26 guidance and delayed commercial ramps, while analysts generally frame these changes as timing related and continue to describe long term potential tied to future program wins and site transfers. Analyst Commentary Recent research shows a mix of optimism and caution around Lifecore Biomedical, with price targets clustering around the mid single digits and views that recent guidance reflects timing shifts rather than a change in the longer term opportunity.Mise à jour du récit • Apr 01
LFCR: CDMO Site Transfers And Late Stage Pipeline Will Drive Future Upside
Narrative Update: Lifecore Biomedical Analysts have reset Lifecore Biomedical’s price expectations into a tighter band, with targets moving from $8.50 to a range of about $5 to $5.50 as they factor in pushed out commercial ramps and FY26 guidance that came in below expectations, while still viewing the long term opportunity as intact. Analyst Commentary Recent research shows a mix of optimism and caution around Lifecore Biomedical, with price targets reset into a US$5 to US$5.50 range and views that focus on timing of growth rather than the existence of the opportunity itself.Mise à jour du récit • Mar 18
LFCR: Delayed Commercial Ramps And CDMO Wins Will Drive Long Term Upside
Narrative Update: Lifecore Biomedical The analyst price target for Lifecore Biomedical has shifted lower, with recent cuts to around the $5 to $5.50 range. This reflects updated views on timing for commercial ramps and FY26 expectations, even as analysts continue to reference the long term opportunity.Article d’analyse • Jan 20
Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Lifecore Biomedical, Inc. ( NASDAQ:LFCR ) is a stock...Seeking Alpha • Jan 14
Lifecore Biomedical: Wins Should Blow Previous 'New Business' Estimates Out Of The Water
Summary Lifecore Biomedical has excess capacity in a market where there is a global shortage of capacity, demand is growing, and new supply cannot be quickly or effectively built. LFCR is a business with real competitive advantages that is executing at a very high level, where the stock has solid downside protection, and earnings power is growing. LFCR is well on their way to $100M in EBITDA versus a current enterprise value of approximately $400M where a 16x multiple would be conservative here. Lifecore Biomedical experienced fantastic execution toward increasing capacity utilization, and it seems as if the necessary elements of earnings power improvement and a re-rating are already in place. Read the full article on Seeking AlphaMise à jour du récit • Jan 08
LFCR: New Index Inclusion And CDMO Agreements Will Support Balanced Outlook
Analysts now place a neutral US$8.75 price target on Lifecore Biomedical, with the change supported by updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors reflect a slightly more cautious yet still constructive outlook on the shares.Mise à jour du récit • Dec 21
LFCR: New Manufacturing Agreements Will Support Steadier Outlook With Balanced Prospects
Analysts have modestly revised their price target for Lifecore Biomedical to about $8.75 per share, citing slightly improved long term profit margin assumptions and a marginally lower discount rate that together support a steadier valuation outlook. What's in the News Lifecore signed a CDMO master services agreement with a new large global pharmaceutical customer to transfer commercial supply of an injectable product from overseas facilities to Lifecore, with potential for the partner to become one of its top five commercial customers (Key Developments).Mise à jour du récit • Dec 07
LFCR: New Supply And Services Agreements Will Drive Shares Higher
Analysts have modestly raised their price target on Lifecore Biomedical to $8.75, reflecting slightly improved discount rate and forward valuation assumptions even as profit margin expectations edge lower. What's in the News Lifecore Biomedical affirmed its transition period 2025 guidance, projecting revenue of approximately $74 million to $76 million and a net loss between $18.4 million and $16.4 million (company guidance filing).Mise à jour du récit • Nov 23
LFCR: New Program Wins Will Drive Shares Higher Amid Pipeline Transition
Analysts have kept their price target for Lifecore Biomedical steady at $8.75, citing a need for new program wins or contractual step-ups to drive meaningful valuation expansion as the company shifts toward faster-growing markets. Analyst Commentary Recent commentary from the Street highlights both optimism and caution regarding Lifecore Biomedical's outlook.Mise à jour du récit • Nov 06
LFCR: Future Program Wins Will Drive Upside As Pipeline Expands
Analysts have lowered their fair value estimate for Lifecore Biomedical from $10.00 to $8.75 per share. They cited moderated growth assumptions and the need for additional program wins to drive valuation expansion.Article d’analyse • Jul 18
Lifecore Biomedical (NASDAQ:LFCR) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • May 02
A Piece Of The Puzzle Missing From Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Share Price
With a price-to-sales (or "P/S") ratio of 1.9x Lifecore Biomedical, Inc. ( NASDAQ:LFCR ) may be sending bullish signals...Seeking Alpha • Mar 03
Lifecore Biomedical: We Are Not Playing To Make 5% Or 10% Here
Summary Lifecore Biomedical can triple production without additional capital, driven by increased volumes, cost containment, and potential new contracts, boosting EBITDA margins from 15% to 25%+. Alcon's contractual minimum volume step-ups, estimated at $25M medium-term and $50M long-term, will significantly drive Lifecore's revenue growth. New CEO Paul Josephs' business development experience and strategic investments position Lifecore for substantial margin improvement and potential multiple expansion. Simple math suggests Lifecore's share price could rise from sub-$7 to $20, with potential for higher multiples and EBITDA margins, aiming for significant returns. Read the full article on Seeking Alpha
Nouveau récit • Jan 26
Over 50 New Opportunities Expected From Business Development Expansion
Expanding business development and operational capacity is expected to drive revenue growth by broadening the customer base and enhancing earning potential.Seeking Alpha • Dec 01
Lifecore Biomedical: An Interesting CDMO Pure Play
Summary Lifecore, a leading CDMO, specializes in sterile injectable pharmaceuticals and is poised to benefit from the growing CDMO market and potential GLP-1 opportunities. The company is doubling production capacity, enhancing financial performance, and attracting new customers with advanced technology and strategic investments. Despite a challenging Q1, Lifecore anticipates significant revenue growth and improved EBITDA in H2 FY25, driven by increased capacity utilization and cost management. With strong market tailwinds, experienced management, and promising financial outlook, Lifecore shares are rated a buy under $7. Read the full article on Seeking AlphaArticle d’analyse • Nov 26
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Soars 36% But It's A Story Of Risk Vs Reward
Despite an already strong run, Lifecore Biomedical, Inc. ( NASDAQ:LFCR ) shares have been powering on, with a gain of...Seeking Alpha • Nov 12
Lifecore Biomedical: Finally A 'Pure Play' CDMO Business
Summary Lifecore has a new CEO, who has turned around three previous CDMOs, as well as a new CFO who was the CFO for another CDMO that was acquired. Lifecore now operates at less than 35% utilization, meaning that it can almost triple revenue with virtually no additional capital required. Margins should improve as volumes increase/capacity is utilized, but, even without growth, there is opportunity on the cost side. Read the full article on Seeking AlphaSeeking Alpha • Jun 24
Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty
Summary Lifecore Biomedical's strategic review process ended in March 2024 with no sale transaction materializing, leaving shareholders with uncertain prospects. The company, specializing in biomaterials for pharmaceutical and medical sectors, faces financial distress risk due to high leverage and cyclical sector challenges. A fair equity value of $6 per share, with a 20% upside, is suggested based on a comparable transaction, but risks including debt, leverage, and sector uncertainty jeopardize this potential upside. Read the full article on Seeking AlphaSeeking Alpha • Apr 20
White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge
Summary In our FY 2023 letter, we noted our less-than-ideal experience with merger-arbitrage strategies, with Lifecore Biomedical being the sole remaining investment of this nature in the portfolio. We bought more shares at $4.8 per share to bring Lifecore back to a 3% position. Lifecore is increasing capacity and most of this capacity is already paid for, potentially leading to a surge in free cash flow. Read the full article on Seeking AlphaArticle d’analyse • Jun 30
Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Oct 06
Landec Non-GAAP EPS of -$0.32, revenue of $43.35M
Landec press release (NASDAQ:LNDC): Q1 Non-GAAP EPS of -$0.32. Revenue of $43.35M (+4.1% Y/Y). Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year period Lifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year period Consolidated adjusted EBITDA of $(1.1) million, compared to $2.5 million in the prior year period FISCAL 2023 OUTLOOK:The Company is reiterating its full year fiscal 2023 guidance for its Lifecore and Corporate segments. Lifecore segment revenue: range of $122 million to $126 million (+12% to +15%) Lifecore segment adjusted EBITDA: range of $31.0 million to $32.5 million (+7% to +12%) Other segment (corporate expense): range of ($7.0) million to ($7.5) million Consolidated adjusted EBITDA: range of $23.5 million to $25.5 millionSeeking Alpha • Sep 09
Landec receives Nasdaq's notification on delayed annual report filing
Landec (NASDAQ:LNDC) stated Friday that it has been notified by Nasdaq for not in compliance with exchange's listing rules as the company failed to file its annual report for the year ended May 29, 2022. Source: Press ReleaseRendement pour les actionnaires
| LFCR | US Life Sciences | US Marché | |
|---|---|---|---|
| 7D | -6.7% | 0.1% | 0.6% |
| 1Y | -42.8% | 15.6% | 19.5% |
Rendement vs Industrie: LFCR a sous-performé le secteur US Life Sciences qui a rapporté 15.6 % au cours de l'année écoulée.
Rendement vs marché: LFCR a sous-performé le marché US qui a rapporté 19.5 % au cours de l'année écoulée.
Volatilité des prix
| LFCR volatility | |
|---|---|
| LFCR Average Weekly Movement | 8.1% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: LFCR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de LFCR ( 8% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1965 | 382 | Paul Josephs | www.lifecore.com |
Lifecore Biomedical, Inc. et ses filiales opèrent en tant qu'organisation intégrée de développement et de fabrication sous contrat qui sert des clients aux États-Unis, en Belgique, aux Pays-Bas et dans le monde entier. Elle fournit des services de développement, de fabrication, de remplissage aseptique et de finition de formulations et de produits pharmaceutiques injectables stériles hautement visqueux ou de dispositifs médicaux dans des seringues, des flacons et des cartouches selon diverses modalités. La société fabrique et vend également de l'acide hyaluronique de qualité pharmaceutique en vrac, ainsi que pour une utilisation dans des seringues et des flacons formulés et remplis pour des produits injectables utilisés dans le traitement de diverses conditions et procédures médicales, y compris des applications ophtalmiques et orthopédiques.
Lifecore Biomedical, Inc. Résumé des fondamentaux
| LFCR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$178.17m |
| Bénéfices(TTM) | -US$34.50m |
| Recettes(TTM) | US$129.46m |
1.4x
Ratio P/S-5.2x
Ratio P/ELe site LFCR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| LFCR compte de résultat (TTM) | |
|---|---|
| Recettes | US$129.46m |
| Coût des recettes | US$88.85m |
| Marge brute | US$40.61m |
| Autres dépenses | US$75.11m |
| Les revenus | -US$34.50m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.92 |
| Marge brute | 31.37% |
| Marge bénéficiaire nette | -26.65% |
| Ratio dettes/capitaux propres | 383.3% |
Quelles ont été les performances à long terme de LFCR?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/10 02:00 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Lifecore Biomedical, Inc. est couverte par 12 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Brian Holland | D.A. Davidson & Co. |